Journals / Tüberküloz ve Toraks / 2020 / Cilt: 68 - Sayı: 2

Pathological features of COVID-19 infection from biopsy and autopsy series

COVID-19 infeksiyonunun otopsi ve biyopsi raporlarına göre patolojik özellikleri

Pages
160–167
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Given these aforementioned data, in the current manuscript we have summarized the pathological features of COVID-19 derived from biopsy and autopsy series.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Novel coronavirus disease 2019 (COVID-19) which is caused by severe acuterespiratory syndrome corona virus 2 (SARS-CoV-2) was first identified inDecember 2019 in Chinese town Wuhan and considered as a pandemic byWorld Health Organization.
📊
Key Findings & Data:Until now, more than 3.5 million peopleworldwide were infected and more than 240.000 mortality has beenoccurred.
💡
Conclusion & Impact:Given these aforementioned data, in the current manuscript we have summarized the pathological features of COVID-19 derived from biopsy and autopsy series.
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Abstract

Novel coronavirus disease 2019 (COVID-19) which is caused by severe acuterespiratory syndrome corona virus 2 (SARS-CoV-2) was first identified inDecember 2019 in Chinese town Wuhan and considered as a pandemic byWorld Health Organization. The disease has variety of symptoms includingfever, shortness of breath, cough, fatigue, loss of smell and taste and diarrhea.While the majority of cases have mild symptoms, some progress to viral pneumonia, multi-organ failure, or cytokine storm and mortality is mostly causedby hypoxemic respiratory failure. Until now, more than 3.5 million peopleworldwide were infected and more than 240.000 mortality has beenoccurred. Thus, there is now evidence the disease may affect variety of organsaccording to accumulating biopsy and autopsy studies. Such pathologicalstudies have potential role on the understanding of clinical outcomes and inthe development of novel targeted therapeutic approaches. Given these aforementioned data, in the current manuscript we have summarized the pathological features of COVID-19 derived from biopsy and autopsy series.

Özet

Yeni koronavirüs 2019 hastalığı (COVID-19) akut respiratuvar sendromu korona virüs 2 (SARS-COV-2) ilk olarak Çin’in Wuhan şehrinde aralık 2019 tarihinde saptanmış olup, dünya sağlık örgütü tarafından pandemi olarak kabul edilmiştir. COVID-19 infeksiyonu ateş, nefes darlığı, öksürük, halsizlik, ishal, koku ve tat alma bozukluğu gibi şikayetlere neden olabilmektedir. Hastalık yüksek oranda asemptomatik geçirilse bile bazı hastalarda viral pnömoni, solunum yetmezliği, çoklu organ yetmezliği ve sitokin fırtınası gelişebilmekte ve ölüme neden olabilmektedir. Şimdiye kadar 3.5 milyonun üzerinde insan enfekte olmuş olup, 240.000 üzerinde insan ölmüştür. Biyopsi ve otopsi raporlarında akciğer dışı birçok organında tutulduğu gösterilmiştir. Bu bilgilerin yeni tedavi modalitelerinin gelişmesine yardımcı olabileceği ümit edilmektedir. Bu derlemede COVID-19 infeksiyonu olan hastalarda yapılmış biyopsi ve otopsi raporlarında covid enfeksiyonuna bağlı organ tutulumları ve tipleri detaylıca tartışılmıştır

🔖

Cite This Article

ÇOPUR, S., KANBAY, M., KANBAY, A., AFŞAR, B., AFŞAR, R. E. (2022). Pathological features of COVID-19 infection from biopsy and autopsy series. Tüberküloz ve Toraks, Cilt: 68 - Sayı: 2, 160–167. https://ajindex.com/articles/618352

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses 2020;12(4)
  2. Li LQ, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB, et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol 2020
  3. Rodriguez-Morales AJ, Cardona-Ospina JA, GutierrezOcampo E, Villamizar-Pena R, Holguin-Rivera Y, EscaleraAntezana JP, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Medicine and Infectious Disease 2020;101623
  4. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA 2020
  5. Gu J, Han B, Wang J. COVID-19: gastrointestinal manifestations and potential fecal–oral transmission. Gastroenterology 2020
  6. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARSCoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Medicine 2020;1-5
  7. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Medicine 2020;1-3
  8. Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clinical Chemistry and Laboratory Medicine (CCLM) 2020;1(ahead-of-print)
  9. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet 2020
  10. Gordon CJ, Tchesnokov EP, Woolner E, Perry JK, Feng JY, Porter DP, et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. Journal of Biological Chemistry 2020;jbc. RA120.013679
  11. Turner AJ, Hiscox JA, Hooper NM. ACE2: from vasopeptidase to SARS virus receptor. Trends in Pharmacological Sciences 2004;25(6):291-4
  12. Sriram K, Insel PA. Risks of ACE inhibitor and ARB usage in COVID‐19: evaluating the evidence. Clinical Pharmacology & Therapeutics 2020
  13. Rico-Mesa JS, White A, Anderson AS. Outcomes in patients with COVID-19 infection taking ACEI/ARB. Current Cardiol